Bellicum Pharmaceuticals - BLCM Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $5.00
  • Forecasted Upside: 390.20 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.02
▲ +0.02 (2.00%)

This chart shows the closing price for BLCM by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bellicum Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BLCM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BLCM

Analyst Price Target is $5.00
▲ +390.20% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Bellicum Pharmaceuticals in the last 3 months. The average price target is $5.00, with a high forecast of $5.00 and a low forecast of $5.00. The average price target represents a 390.20% upside from the last price of $1.02.

This chart shows the closing price for BLCM for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 investment analysts is to buy stock in Bellicum Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/9/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2022LADENBURG THALM/SH SHInitiated CoverageBuy$5.00Medium
10/30/2020LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralHigh
10/30/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$4.50High
3/13/2020Raymond JamesLower TargetOutperform$40.00 ➝ $17.00High
2/14/2020Wells Fargo & CompanyBoost Target$4.00 ➝ $18.00Low
8/9/2018CitigroupLower TargetBuy ➝ Buy$220.00 ➝ $190.00High
8/7/2018Cantor FitzgeraldSet TargetBuy$180.00High
5/9/2018Cantor FitzgeraldSet TargetBuy$180.00Medium
4/11/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$83.00 ➝ $68.50High
4/11/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$100.00 ➝ $180.00High
3/13/2018Cantor FitzgeraldSet TargetBuy$100.00Low
2/23/2018Cantor FitzgeraldSet TargetBuy$100.00High
2/16/2018CitigroupBoost TargetBuy ➝ Hold$240.00 ➝ $270.00High
1/31/2018SunTrust BanksLower TargetHold ➝ Buy$180.00High
1/31/2018Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$120.00 ➝ $100.00High
1/31/2018Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$60.00High
12/12/2017Raymond JamesReiterated RatingBuyHigh
(Data available from 12/4/2017 forward)

News Sentiment Rating

0.58 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/8/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/7/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/6/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/5/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/5/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/4/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/4/2022

Current Sentiment

  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.
Bellicum Pharmaceuticals logo
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
Read More

Today's Range

Now: $1.02
Low: $0.99
High: $1.06

50 Day Range

MA: $1.07
Low: $0.94
High: $1.25

52 Week Range

Now: $1.02
Low: $0.93
High: $2.20

Volume

4,009 shs

Average Volume

7,480 shs

Market Capitalization

$8.78 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.24

Frequently Asked Questions

What sell-side analysts currently cover shares of Bellicum Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Bellicum Pharmaceuticals in the last twelve months: LADENBURG THALM/SH SH, StockNews.com, and TheStreet.
View the latest analyst ratings for BLCM.

What is the current price target for Bellicum Pharmaceuticals?

1 Wall Street analysts have set twelve-month price targets for Bellicum Pharmaceuticals in the last year. Their average twelve-month price target is $5.00, suggesting a possible upside of 390.2%. LADENBURG THALM/SH SH has the highest price target set, predicting BLCM will reach $5.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $5.00 for Bellicum Pharmaceuticals in the next year.
View the latest price targets for BLCM.

What is the current consensus analyst rating for Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe BLCM will outperform the market and that investors should add to their positions of Bellicum Pharmaceuticals.
View the latest ratings for BLCM.

What other companies compete with Bellicum Pharmaceuticals?

How do I contact Bellicum Pharmaceuticals' investor relations team?

Bellicum Pharmaceuticals' physical mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company's listed phone number is (832) 384-1100 and its investor relations email address is [email protected] The official website for Bellicum Pharmaceuticals is www.bellicum.com. Learn More about contacing Bellicum Pharmaceuticals investor relations.